Repurposing of Drugs Targeted Against COVID-19 Spike Receptor for Treatment: An In silico Approach

Abstract

An escalating pandemic by the novel SARS-CoV2 is spreading across the globe at a rate. An urgent need for therapy is needed. Initially, the virus appeared first in Wuhan, China, and later approximately in 187 countries worldwide. Coronaviruses are causative of respiratory as well as neurological diseases in humans. The novel zoonotic disease-causing coronaviruses are single-stranded RNA viruses. The coronavirus's outer structure consists of spike protein made up of glycoproteins, which binds to ACE (Angiotensin Converting Enzyme) protein when infected in humans. In the current study, 37 compounds that are already used in the biological field as anti-viral compounds are observed with bioinformatics tools. The repurposing drugs are docked against the spike receptor by molecular Docking. The ligand structure and the receptor structure are retrieved from Protein Data Bank. Patch dock server is an open freeware available for docking procedures. The results include acceleration and score of matched properties showing the feasibility of working the drug against SARS-nCoV. For the visualization of the final docked product, PyMOL and RasWin software’s are used. The scores of each ligand docked against the receptor show the compatibility working against the COVID-19 disease.